C-Type Lectin Domain Family 9 Member A (CLEC9A) Antibody (Biotin)
169€ (20 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
C-Type Lectin Domain Family 9 Member A (CLEC9A) Antibody (Biotin)
category
Primary Antibodies
provider
Abbexa
reference
abx313456
tested applications
ELISA
Description
CLEC9A Antibody (Biotin) is a Rabbit Polyclonal against CLEC9A conjugated to Biotin.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | C-Type Lectin Domain Family 9 Member A (CLEC9A) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Biotin |
| Isotype | IgG |
| Purity | > 95% |
| Purification | Purified by Protein G. |
| Size 1 | 20 µg |
| Size 2 | 50 µg |
| Size 3 | 100 µg |
| Size 4 | 200 µg |
| Size 5 | 1 mg |
| Form | Liquid |
| Tested Applications | ELISA |
| Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% Glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q6UXN8 |
| Gene ID | 283420 |
| OMIM | 612252 |
| Alias | CD370,DNGR1,DNGR-1, |
| Background | Antibody anti-CLEC9A |
| Status | RUO |
| Note | Concentration: 0.278 mg/ml - |
Descripción
CLEC9A, also known as C-type lectin domain family 9 member A or DNGR-1 (Dendritic Cell Natural Killer Lectin Group Receptor 1), is an immune receptor primarily expressed on a subset of dendritic cells (DCs) and certain populations of macrophages. CLEC9A is part of the C-type lectin receptor (CLR) family, which is known for its role in recognizing carbohydrate structures on pathogens, triggering immune responses, and presenting antigens to T cells. However, CLEC9A is unique within this family for its specialized function in detecting necrotic cells and facilitating the cross-presentation of antigens from dead cells. This capability enables CLEC9A to bridge innate and adaptive immunity, playing a significant role in immune responses to infections, cancer, and tissue injury.The receptor's ability to recognize damaged cells, rather than simply pathogens, underscores its importance in contexts such as infection, cancer immunology, and autoimmunity. CLEC9A has therefore gained interest for its potential applications in vaccine development and immunotherapy. Its expression is mainly restricted to CD8+ DCs and their human equivalent, BDCA3+ DCs, which are specialized for cross-presentation, making CLEC9A a critical component in inducing CD8+ T cell responses.
Related Products
CLEC9A antibody
Functions as an endocytic receptor on a small subset of myeloid cells specialized for the uptake and processing of material from dead cells. Recognizes filamentous form of actin in association with particular actin-binding domains of cytoskeletal proteins, including spectrin, exposed when cell membranes are damaged, and mediate the cross-presentation of dead-cell associated antigens in a Syk-dependent manner.
Ver Producto
Recombinant Human CLEC9A
Ver Producto
C-Type Lectin Domain Family 9 Member A (CLEC9A) Antibody
CLEC9A is a group V C-type lectin-like receptor (CTLR) that functions as an activation receptor and is expressed on myeloid lineage cells (Huysamen et al., 2008 [PubMed 18408006]).
Ver Producto